35 districts benefit from malaria vaccine pilot project ghanaiantimes.com.gh - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanaiantimes.com.gh Daily Mail and Mail on Sunday newspapers.
01/27/2021 | Press release | Distributed by Public on 01/27/2021 06:02
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
For media and investors only
Issued: London, UK
Bharat Biotech to produce antigen for world s first vaccine against Plasmodium falciparum malaria following technology transfer, to help ensure long-term sustainable supply
Transfer builds on GSK commitments to donate up to 10 million vaccine doses to the pilot implementation in regions of Ghana, Kenya, and Malawi and supply up to 15 million doses annually to 2028 if recommended for wider use
Bharat Biotech selected as partner based upon its established experience in development, production, and supply of global health vaccines
Hyderabad: Indigenous pharmaceutical company Bharat Biotech will create antigen for the first anti-malaria vaccine. For this, an agreement (..|News Track
GSK, PATH, and Bharat Biotech (BBIL) Wednesday announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E. The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL.
Malaria life cycle/CDC
BBIL is an established, innovative biotechnology company based in Hyderabad, India, focused on delivering safe, affordable, and high-quality vaccines and bio-therapeutics against infectious diseases. The agreement recognises the track record and expertise of BBIL in developing and supplying vaccines against infectious diseases, including as an established supplier of global health vaccines to Gavi, the Vaccine Alliance, and to UNICEF. BBIL was selected through a comprehensive, competitive process undertaken by GSK and PATH, working in consul